AR080585A1 - Vacunacion contra tumores que comprende una respuesta inmune humoral contra proteinas propias - Google Patents
Vacunacion contra tumores que comprende una respuesta inmune humoral contra proteinas propiasInfo
- Publication number
- AR080585A1 AR080585A1 ARP110100809A ARP110100809A AR080585A1 AR 080585 A1 AR080585 A1 AR 080585A1 AR P110100809 A ARP110100809 A AR P110100809A AR P110100809 A ARP110100809 A AR P110100809A AR 080585 A1 AR080585 A1 AR 080585A1
- Authority
- AR
- Argentina
- Prior art keywords
- tumor
- protein
- tumors
- antigen
- proteins
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 8
- 102000004169 proteins and genes Human genes 0.000 title abstract 7
- 108090000623 proteins and genes Proteins 0.000 title abstract 7
- 238000002255 vaccination Methods 0.000 title abstract 2
- 230000008348 humoral response Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 102000002029 Claudin Human genes 0.000 abstract 2
- 108050009302 Claudin Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102100040835 Claudin-18 Human genes 0.000 abstract 1
- 102100038449 Claudin-6 Human genes 0.000 abstract 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 101000749329 Homo sapiens Claudin-18 Proteins 0.000 abstract 1
- 101000882898 Homo sapiens Claudin-6 Proteins 0.000 abstract 1
- 101000691463 Homo sapiens Placenta-specific protein 1 Proteins 0.000 abstract 1
- 102100026181 Placenta-specific protein 1 Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000028996 humoral immune response Effects 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10141—Use of virus, viral particle or viral elements as a vector
- C12N2730/10143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se relaciona con la inmunoterapia de los tumores, particularmente con la vacunacion contra los tumores, mediante el uso de proteínas quiméricas que comprenden la totalidad o una porcion de la proteína antigénica principal del virus de la hepatitis B y una secuencia de aminoácidos que comprende un epítope derivado de una porcion extracelular de un antígeno asociado a un tumor. En particular, se proveen partículas similares a virus que comprenden dichas proteínas quiméricas para provocar una respuesta inmune humoral en un sujeto contra el antígeno asociado al tumor, particularmente contra las células que contienen dicho antígeno asociado a un tumor en su superficie, donde el antígeno asociado al tumor es una proteína propia de dicho sujeto. Proteína. Vector. Acido nucleico. Composicion inmunologica. Reivindicacion 3: La proteína de la reivindicacion 1 o 2, caracterizada porque el antígeno asociado al tumor es una proteína de la familia de la claudina o PLAC1, donde la proteína de la familia de la claudina preferiblemente se selecciona del grupo que consiste en CLDN18.2 y CLDN6.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10002775A EP2366709A1 (en) | 2010-03-16 | 2010-03-16 | Tumor vaccination involving a humoral immune response against self-proteins |
EP10016216 | 2010-12-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR080585A1 true AR080585A1 (es) | 2012-04-18 |
Family
ID=43855962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110100809A AR080585A1 (es) | 2010-03-16 | 2011-03-14 | Vacunacion contra tumores que comprende una respuesta inmune humoral contra proteinas propias |
Country Status (9)
Country | Link |
---|---|
US (3) | US8840902B2 (es) |
EP (1) | EP2547695B1 (es) |
JP (2) | JP6199036B2 (es) |
AR (1) | AR080585A1 (es) |
AU (1) | AU2011229518B2 (es) |
CA (1) | CA2786940C (es) |
ES (1) | ES2675825T3 (es) |
TR (1) | TR201809413T4 (es) |
WO (1) | WO2011113546A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
CA2786940C (en) | 2010-03-16 | 2019-09-24 | Biontech Ag | Tumor vaccination involving a humoral immune response, and proteins therefor including all or a portion of a hepatitis b virus core antigen protein and an epitope of claudin 18.2 |
WO2013167153A1 (en) * | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
UA128182C2 (uk) | 2012-11-13 | 2024-05-01 | Біонтех Аґ | Агенти для лікування експресуючих клаудин ракових захворювань |
PL3708579T3 (pl) * | 2014-04-01 | 2024-08-05 | Biontech Cell & Gene Therapies Gmbh | Immunoreceptory specyficzne dla klaudyny-6 i epitopy komórek t |
CN104293741A (zh) * | 2014-10-10 | 2015-01-21 | 武汉大学 | 一种呼吸道合胞病毒病毒样颗粒疫苗及其制备方法和应用 |
WO2016180468A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Claudin-18.2-specific immunoreceptors and t cell epitopes |
AU2018240421A1 (en) * | 2017-03-24 | 2019-09-26 | BioNTech SE | Methods and compositions for stimulating immune response |
BR112020015479A2 (pt) | 2018-03-08 | 2020-12-08 | Phanes Therapeutics, Inc. | Anticorpos anticlaudina 18.2 e usos dos mesmos |
WO2020191342A1 (en) | 2019-03-20 | 2020-09-24 | The Regents Of The University Of California | Claudin-6 antibodies and drug conjugates |
CN114560941B (zh) * | 2020-11-27 | 2024-01-16 | 广东东阳光药业股份有限公司 | Cldn18.2的抗体及其应用 |
CN114836388A (zh) * | 2022-06-07 | 2022-08-02 | 江苏亲科生物研究中心有限公司 | Claudin18.2单克隆抗体及其制备方法和用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
AU2540897A (en) * | 1996-03-21 | 1997-10-10 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods and compositions of chimeric polypeptides for tumor antigen vaccines |
PT1268530E (pt) * | 2000-04-07 | 2006-12-29 | Univ Leeds | Proteínas de fusão do antigénio do core da hepatite b |
AU2002339224B2 (en) * | 2001-09-14 | 2008-10-09 | Kuros Us Llc | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
DE10254601A1 (de) * | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
KR20050115913A (ko) | 2003-03-26 | 2005-12-08 | 사이토스 바이오테크놀로지 아게 | Melan―a 펩티드 유사체-바이러스-양-입자컨쥬게이트 |
EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
US20110104191A1 (en) | 2007-09-11 | 2011-05-05 | Universite Laval | Malva mosaic virus and virus-like particles and uses thereof |
DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
SG10201402493UA (en) * | 2009-02-20 | 2014-10-30 | Ganymed Pharmaceuticals Ag | Methods and compositions for diagnosis and treatment of cancer |
CN101584860A (zh) * | 2009-04-27 | 2009-11-25 | 西安杰诺瓦生物科技有限公司 | 重组人Claudin18.2肿瘤疫苗及其制备方法 |
CA2786940C (en) | 2010-03-16 | 2019-09-24 | Biontech Ag | Tumor vaccination involving a humoral immune response, and proteins therefor including all or a portion of a hepatitis b virus core antigen protein and an epitope of claudin 18.2 |
-
2011
- 2011-03-09 CA CA2786940A patent/CA2786940C/en active Active
- 2011-03-09 TR TR2018/09413T patent/TR201809413T4/tr unknown
- 2011-03-09 EP EP11707355.1A patent/EP2547695B1/en active Active
- 2011-03-09 JP JP2012557436A patent/JP6199036B2/ja active Active
- 2011-03-09 WO PCT/EP2011/001168 patent/WO2011113546A1/en active Application Filing
- 2011-03-09 US US13/634,696 patent/US8840902B2/en active Active
- 2011-03-09 ES ES11707355.1T patent/ES2675825T3/es active Active
- 2011-03-09 AU AU2011229518A patent/AU2011229518B2/en active Active
- 2011-03-14 AR ARP110100809A patent/AR080585A1/es active IP Right Grant
-
2014
- 2014-08-12 US US14/457,897 patent/US9617321B2/en active Active
-
2016
- 2016-07-08 JP JP2016135704A patent/JP2017025057A/ja active Pending
- 2016-11-02 US US15/341,528 patent/US10526387B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10526387B2 (en) | 2020-01-07 |
US8840902B2 (en) | 2014-09-23 |
AU2011229518B2 (en) | 2015-09-24 |
US20150152154A1 (en) | 2015-06-04 |
TR201809413T4 (tr) | 2018-07-23 |
US20170072035A1 (en) | 2017-03-16 |
US20130052217A1 (en) | 2013-02-28 |
CA2786940C (en) | 2019-09-24 |
JP2017025057A (ja) | 2017-02-02 |
EP2547695A1 (en) | 2013-01-23 |
JP6199036B2 (ja) | 2017-09-20 |
JP2013521785A (ja) | 2013-06-13 |
CA2786940A1 (en) | 2011-09-22 |
ES2675825T3 (es) | 2018-07-12 |
AU2011229518A1 (en) | 2012-08-30 |
US9617321B2 (en) | 2017-04-11 |
EP2547695B1 (en) | 2018-05-09 |
WO2011113546A1 (en) | 2011-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR080585A1 (es) | Vacunacion contra tumores que comprende una respuesta inmune humoral contra proteinas propias | |
CO2018005229A2 (es) | Vacuna de virus sincitial respiratorio | |
CR20170419A (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. | |
WO2010104749A3 (en) | Antigen presenting cell targeted cancer vaccines | |
PH12015500308A1 (en) | Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same | |
WO2010104761A3 (en) | Anti-cd40 antibodies and uses thereof | |
MX2023006203A (es) | Vacunas novedosas contra el virus de zika. | |
MX2013008836A (es) | Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso. | |
EP3708185A3 (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll) | |
WO2014018858A3 (en) | Multimeric fusion protein vaccine and immunotherapeutic | |
WO2017210579A8 (en) | Compositions and methods for tumor vaccination and immunotherapy involving her2/neu | |
EA201071297A1 (ru) | Новые и действенные пептиды мнс ii класса, полученные из сурвивина | |
MX337397B (es) | Vacunas anti-virales dirigidas a celulas que presentan antigeno. | |
WO2011113819A3 (en) | Diagnosis and treatment of cancer based on avl9 | |
MX349657B (es) | Composiciones de vacuna de matriz de proteína que incluyen policationes. | |
EA201590829A1 (ru) | Новые мукозные адъюванты и системы доставки | |
EA201892735A1 (ru) | Состав вакцины против hiv | |
WO2009114085A3 (en) | Allogeneic cancer cell-based immunotherapy | |
MX2013013228A (es) | Particulas similares a virus y proceso para prepararlas. | |
PH12014501795A1 (en) | Rota virus subunit vaccines and methods of making and use thereof | |
EA201400216A1 (ru) | Консервирование биологических продуктов, в частности вакцин, с применением вакуума | |
CY1125328T1 (el) | Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων | |
WO2012038832A3 (en) | Generation of replicating chimeric measles virus - retrovirus particles | |
MX2019007924A (es) | Vacunas contra la influenza. | |
MX2016009952A (es) | Proteinas y antigenos del virus de diarrea epidemica porcino (pedv). |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |